Jiro JIRO

Dr. Jiro JIRO

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2007 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
JYJunichi Yamanaka
Junichi Yamanaka
SSShinichi Saito
Shinichi Saito
JJJiro JIRO
Jiro JIRO

26 November 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NUNaoki Uyama
Naoki Uyama
HTHiroko Tsutsui
Hiroko Tsutsui
SWSongtao Wu
Songtao Wu
KYKoubun Yasuda
Koubun Yasuda
EHEtsuro Hatano
Etsuro Hatano
JJJiro JIRO
Jiro JIRO
Postoperative adhesion formation often ruins the quality of life or is an obstacle to illnesses with curative operation such as cancer. Previously we demonstrated that interferon-γ-promoted fibrin deposition drove postoperative adhesion formation. However, its underlying cellular and molecular mechanisms remain poorly understood. We found that myofibroblasts of the adhesion predominantly expressed signature molecules of mesothelial cells that line the serosa. Microarray analysis revealed IL-6 as a key underlying player, supported by elevated IL-6 levels in the peritoneal fluid of post-laparotomy human subjects. Injured serosa of cecum-cauterized mice also exhibited induction of Il6, which was followed by Tnf, concomitant with rapid accumulation of neutrophils, substantial population of which expressed TGF-β1, a master regulator of fibrosis. Besides, neutrophil-ablated mice showed reduction in induction of the adhesion, suggesting that TGF-β1+neutrophils triggered the adhesion. Human neutrophils expressed TGFB1 in response to TNF-α and TNF in response to IL-6. Moreover, anti-IL-6 receptor monoclonal antibody abrogated neutrophil recruitment and adhesion formation. Thus, IL-6 signaling represents a potential target for the prevention of postoperative adhesions.

5 August 2008 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
HKHironari Kanemura
Hironari Kanemura
YIYuji Iimuro
Yuji Iimuro
MTMasaharu Takeuchi
Masaharu Takeuchi
TUTakahiro Ueki
Takahiro Ueki
THTadamichi Hirano
Tadamichi Hirano
JJJiro JIRO
Jiro JIRO

26 June 2013 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
HKHisashi Kosaka
Hisashi Kosaka
NKNobukazu Kuroda
Nobukazu Kuroda
KSKazuhiro Suzumura
Kazuhiro Suzumura
YAYasukane Asano
Yasukane Asano
TOToshihiro Okada
Toshihiro Okada
JJJiro JIRO
Jiro JIRO

1 April 2014 in Surgery
Verified
Journal Article
Closed access
HSHideaki Sueoka
Hideaki Sueoka
THTadamichi Hirano
Tadamichi Hirano
YUYugo Uda
Yugo Uda
YIYuji Iimuro
Yuji Iimuro
JYJunichi Yamanaka
Junichi Yamanaka
JJJiro JIRO
Jiro JIRO

19 July 2006 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
TKTakanori Kuroiwa
Takanori Kuroiwa
TITsuyoshi Iwasaki
Tsuyoshi Iwasaki
TITakehito Imado
Takehito Imado
MSMasahiro Sekiguchi
Masahiro Sekiguchi
JJJiro JIRO
Jiro JIRO
HSHajime Sano
Hajime Sano
Chronic graft-versus-host disease (GVHD) induced in (C57BL/6 × DBA/2) F1 (BDF1) mice by the injection of DBA/2 mouse spleen cells represents histopathological changes associated with systemic lupus erythematosus (SLE), primary biliary cirrhosis (PBC) and Sjogren's syndrome (SS), as indicated by glomerulonephritis, lymphocyte infiltration into the periportal area of the liver and salivary glands. We determined the therapeutic effect of hepatocyte growth factor (HGF) gene transfection on lupus using this chronic GVHD model. Chronic GVHD mice were injected in the gluteal muscle with either HVJ liposomes containing 8 μg of the human HGF expression vector (HGF-HVJ liposomes) or mock vector (untreated control). Gene transfer was repeated at 2-week intervals during 12 weeks. HGF gene transfection effectively prevented the proteinuria and histopathological changes associated with glomerulonephritis. While liver and salivary gland sections from untreated GVHD mice showed prominent PBC- and SS-like changes, HGF gene transfection reduced these histopathological changes. HGF gene transfection greatly reduced the number of splenic B cells, host B cell major histocompatibility complex class II expression, and serum levels of IgG and anti-DNA antibodies. IL-4 mRNA expression in the spleen, liver, and kidneys was significantly decreased by HGF gene transfection. CD28 expression on DBA/2 CD4+ T cells was decreased by the addition of recombinant HGF in vitro. Furthermore, IL-4 production by DBA/2 CD4+ T cells stimulated by irradiated BDF1 dendritic cells was significantly inhibited by the addition of recombinant HGF in vitro. These results suggest that HGF gene transfection inhibited T helper 2 immune responses and reduced lupus nephritis, autoimmune sialoadenitis, and cholangitis in chronic GVHD mice. HGF may represent a novel strategy for the treatment of SLE, SS and PBC.